MiniMed (MMED) closed at $22.42 on Sep 1, 2026, up 10.7% on the day. The stock is up 17.4% over the past month and up 82.3% over three months. It trades 1.4% below its 52-week high of $22.74 and 110.5% above its 52-week low of $10.65. The close sits above its 50-day moving average ($17.61).
Over its last 2 reports the stock moved an average of 13.3% on the first trading day after earnings, beating the options-implied move in 1 of 2.
Over the last 2 reports, MMED moved an average of 13.3% on the first trading day after earnings. The move beat the options-implied move in 1 of 2 reports.
MMED closed 1.4% below its 52-week high of $22.74.
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, such as insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera Sync, or Guardian 4 sensor, and wraparound applications and services. It also offers CareLink, a software platform that provides support for person with diabetes, their caretakers, and HCPS. MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California. MiniMed Group, Inc. operates as a subsidiary of Medtronic plc.
